Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.1 HKD | +4.37% | -1.38% | +20.10% |
Sales 2024 * | 677M 93.63M 732M | Sales 2025 * | 1.5B 208M 1.62B | Capitalization | 7.11B 984M 7.69B |
---|---|---|---|---|---|
Net income 2024 * | -646M -89.4M -699M | Net income 2025 * | -160M -22.14M -173M | EV / Sales 2024 * | 9.18 x |
Net cash position 2024 * | 901M 125M 974M | Net cash position 2025 * | 336M 46.51M 363M | EV / Sales 2025 * | 4.51 x |
P/E ratio 2024 * |
-10.9
x | P/E ratio 2025 * |
-44.2
x | Employees | 432 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.82% |
Latest transcript on Everest Medicines Limited
1 day | +4.37% | ||
1 week | -1.38% | ||
Current month | +2.66% | ||
1 month | -2.33% | ||
3 months | +57.86% | ||
6 months | -8.56% | ||
Current year | +20.10% |
Managers | Title | Age | Since |
---|---|---|---|
Yong Qing Luo
CEO | Chief Executive Officer | 54 | 22-09-18 |
Ian Ying Woo
PSD | President | 51 | 18-11-30 |
Michael Berry
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-06-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yi Fan Li
BRD | Director/Board Member | 55 | 20-08-31 |
Honggang Feng
BRD | Director/Board Member | 59 | Feb. 08 |
Wei Fu
CHM | Chairman | 42 | 17-06-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.75% | 4 M€ | -27.92% | ||
0.01% | 4 M€ | -4.41% | - | |
0.00% | 0 M€ | +3.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 25.1 | +4.37% | 2 940 857 |
24-05-08 | 24.05 | 0.00% | 3,760,157 |
24-05-07 | 24.05 | -5.87% | 3,819,918 |
24-05-06 | 25.55 | +2.40% | 4,599,954 |
24-05-03 | 24.95 | -1.96% | 550,566 |
Delayed Quote Hong Kong S.E., May 09, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.10% | 984M | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+51.52% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- 1952 Stock